Clinical Trial Update: A Study of an Ad26.RSV. preF-based Vaccine in Adults Aged 18 to 59 Years, Including Adults at High Risk for Severe RSV Infection [Phase 3]

View source ↗

Summary

Phase 3 trial of an Ad26.RSV.preF-based vaccine for respiratory syncytial virus infection prevention in adults aged 18–59 (including high-risk groups) completed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infection

Drugs mentioned

• Ad26.RSV.preF-based vaccine (Ad26.RSV.preF)

Snippet

Sponsor: Janssen Vaccines & Prevention B.V. | Conditions: Respiratory Syncytial Virus Infection Prevention | Phase 3 | Status: COMPLETED | Results posted: 2023-10-04